Tempest Therapeutics(DE:3OS0)
€5.940.00 (0.00%)
DE:3OS0
Tempest Therapeutics financials statements
€5.94
At close:0.00 (0.00%)
Tempest Therapeutics (3OS0) Ratios
1 Followers
Tempest Therapeutics Ratios
DE:3OS0's free cash flow for Q2 2026 was $-2.78M. For the 2026 fiscal year, DE:3OS0's free cash flow was increased by $0.00 and operating cash flow was $-2.78M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.50 | 2.21 | 4.29 | 4.53 | 3.44 |
| Quick Ratio | 2.50 | 2.21 | 4.29 | 4.53 | 3.44 |
| Cash Ratio | 2.33 | 2.13 | 4.17 | 4.29 | 2.59 |
| Solvency Ratio | -2.53 | -1.85 | -1.17 | -1.25 | -0.75 |
| Operating Cash Flow Ratio | -8.09 | -2.32 | -2.91 | -4.27 | -1.30 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -5.20 | -6.38 | 0.00 | 0.00 |
| Net Current Asset Value | $ -1.99M | $ 9.11M | $ 15.53M | $ 4.97M | $ 31.84M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.48 | 0.37 | 0.40 | 0.48 | 0.25 |
| Debt-to-Equity Ratio | 1.22 | 0.80 | 0.77 | 1.22 | 0.51 |
| Debt-to-Capital Ratio | 0.55 | 0.45 | 0.44 | 0.55 | 0.34 |
| Long-Term Debt-to-Capital Ratio | 0.51 | 0.00 | 0.19 | 0.36 | 0.29 |
| Financial Leverage Ratio | 2.54 | 2.17 | 1.93 | 2.54 | 2.03 |
| Debt Service Coverage Ratio | -124.58 | -5.23 | -4.82 | -20.68 | -20.78 |
| Interest Coverage Ratio | -128.38 | -31.93 | -20.12 | -21.41 | -21.05 |
| Debt to Market Cap | 0.58 | 0.02 | 0.16 | 0.78 | 9.81 |
| Interest Debt Per Share | 2.01 | 0.60 | 1.43 | 26.73 | 68.11 |
| Net Debt to EBITDA | -0.02 | 0.37 | 0.67 | 0.27 | 1.25 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 98.82% | 99.56% | 101.15% | 103.09% | 104.88% |
| Return on Assets (ROA) | -155.11% | -100.86% | -57.15% | -77.48% | -38.64% |
| Return on Equity (ROE) | -393.85% | -218.78% | -110.17% | -197.17% | -78.36% |
| Return on Capital Employed (ROCE) | -195.16% | -154.12% | -69.11% | -89.25% | -50.71% |
| Return on Invested Capital (ROIC) | -179.45% | -121.85% | -61.48% | -86.12% | -49.38% |
| Return on Tangible Assets | -155.11% | -100.86% | -57.15% | -77.48% | -38.64% |
| Earnings Yield | -220.51% | -13.82% | -43.48% | -268.98% | -1842.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.16 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -2298.84 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 2298.84 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -6.46 | -1.18 | -1.77 | -34.99 | -89.20 |
| Free Cash Flow Per Share | -6.46 | -1.20 | -1.79 | -35.62 | -89.66 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -75.92 | -160.92 | -55.29 | -192.27 |
| Capital Expenditure Coverage Ratio | 0.00 | -75.92 | -160.92 | -55.29 | -192.27 |
| Operating Cash Flow Coverage Ratio | -3.29 | -2.15 | -1.32 | -1.41 | -1.40 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -225.19% | -11.05% | -40.58% | -238.29% | -1698.17% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.45 | -7.23 | -2.30 | -0.37 | -0.05 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.79 | 15.83 | 2.53 | 0.73 | 0.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.44 | -9.05 | -2.46 | -0.42 | -0.06 |
| Price-to-Operating Cash Flow Ratio | -0.44 | -9.17 | -2.48 | -0.43 | -0.06 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.34 | 0.06 | 0.01 | 0.00 |
| Enterprise Value Multiple | -0.48 | -7.17 | -1.78 | -0.12 | 1.19 |
| Enterprise Value | 12.34M | 287.83M | 49.26M | 4.16M | -31.76M |
| EV to EBITDA | -0.48 | -7.17 | -1.78 | -0.12 | 1.19 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.46 | -8.60 | -1.79 | -0.13 | 1.22 |
| EV to Operating Cash Flow | -0.46 | -8.72 | -1.80 | -0.13 | 1.22 |
| Tangible Book Value Per Share | 1.61 | 0.69 | 1.74 | 20.40 | 124.11 |
| Shareholders’ Equity Per Share | 1.61 | 0.69 | 1.74 | 20.40 | 124.11 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -6.33 | -1.50 | -1.91 | -40.21 | -97.26 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.03 | 1.05 | 1.05 | 1.05 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.02 | 0.79 | 0.93 | 0.87 | 0.92 |
Currency in USD
